πŸ‡ΊπŸ‡Έ FDA
Patent

US 12077587

Anti-CD8 antibodies and uses thereof

granted A61KA61K2039/505A61K45/06

Quick answer

US patent 12077587 (Anti-CD8 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K45/06, A61K49/0032, A61K49/0058